Anuh Pharma Limited has successfully passed a regulatory audit conducted by the European Directorate for the Quality of Medicines & HealthCare (EDQM) at its manufacturing facilities in Maharashtra. The company announced this development through a regulatory filing, highlighting its continued commitment to maintaining international quality standards.

Audit Details and Facility Coverage

The EDQM audit covered three specific manufacturing units operated by Anuh Pharma Limited:

The European Directorate for Quality of Medicines & HealthCare is a leading authority in pharmaceutical quality standards, making this compliance certification particularly significant for the company's operations.

Regulatory Compliance Achievement

The successful audit outcome demonstrates Anuh Pharma Limited's adherence to stringent international quality standards. The company emphasized that this achievement reaffirms its continued commitment to global regulatory and quality compliance standards. Such certifications are essential for pharmaceutical companies seeking to maintain their market presence and expand their reach in international markets.

The compliance status achieved through this audit validates the company's manufacturing processes, quality control systems, and overall operational standards at the Tarapur facilities. This certification ensures that the manufacturing units meet the rigorous requirements set by European regulatory authorities.

Strategic Significance

For pharmaceutical companies like Anuh Pharma Limited, maintaining compliance with international regulatory standards is crucial for business continuity and growth prospects. The successful EDQM audit provides several strategic advantages:

• Validation of manufacturing quality standards
• Enhanced credibility with international partners
• Continued access to regulated markets
• Reinforcement of operational excellence

The company has made this disclosure available on its official website at www.anuhpharma.com , ensuring transparency with stakeholders and regulatory authorities. This successful audit outcome positions Anuh Pharma Limited favorably in terms of regulatory compliance and quality assurance in the pharmaceutical manufacturing sector.

Anuh Pharma Limited has published its unaudited financial results for the quarter ended December 31, 2025, in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The pharmaceutical company announced the publication through advertisements in Financial Express (English) and Mumbai Lakshdeep (Marathi) editions on February 8, 2026.

Financial Performance Highlights

The company demonstrated strong financial performance during the third quarter of FY26. Total revenue from operations reached ₹19,717.81 lakhs, marking substantial growth from ₹15,051.33 lakhs in the corresponding quarter of the previous year. This represents a significant improvement in the company's operational scale and market reach.

| Financial Metric: | Q3 FY26 | Q3 FY25 | Growth || | ---: | :--- | :--- | :--- | | Total Revenue from Operations: | ₹19,717.81 lakhs | ₹15,051.33 lakhs | Strong growth | | Net Profit Before Tax: | ₹1,782.82 lakhs | ₹1,326.55 lakhs | Improved | | Net Profit After Tax: | ₹1,345.10 lakhs | ₹1,034.31 lakhs | Enhanced | | Basic EPS: | ₹1.34 | ₹1.03 | Higher |

Nine Months Performance

For the nine months ended December 31, 2025, Anuh Pharma achieved total revenue from operations of ₹56,954.02 lakhs compared to ₹46,337.54 lakhs in the corresponding period of the previous year. Net profit after tax for the nine-month period stood at ₹2,938.47 lakhs, while the previous year recorded ₹3,489.49 lakhs.

Profitability and Margin Analysis

The company maintained healthy profitability metrics during the quarter. EBITDA for Q3 FY26 was ₹2,091.04 lakhs with an EBITDA margin of 10.60%. The adjusted EBITDA, which accounts for forex gains/losses and mark-to-market on mutual fund investments, reached ₹2,402.53 lakhs, representing an adjusted EBITDA margin of 12.18%.

Share Capital and Earnings

The company's paid-up equity share capital stood at ₹5,011.20 lakhs with a face value of ₹5 per share. Basic and diluted earnings per share for Q3 FY26 were ₹1.34, compared to ₹1.03 in the corresponding quarter of the previous year. For the nine months ended December 31, 2025, basic and diluted EPS were ₹2.93.

Regulatory Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors. The publication includes a Quick Response Code and webpage details where complete financial results are accessible, ensuring transparency and compliance with regulatory requirements. The results are simultaneously available on the company's website at www.anuhpharma.com .